Edition:
United Kingdom

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

46.50USD
19 Jun 2019
Change (% chg)

-- (--)
Prev Close
$46.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,092,578
52-wk High
$47.00
52-wk Low
$12.58

Latest Key Developments (Source: Significant Developments)

Pfizer To Acquire Array Biopharma For $48/share In Cash
Monday, 17 Jun 2019 

June 17 (Reuters) - Array Biopharma Inc ::PFIZER TO ACQUIRE ARRAY BIOPHARMA.ARRAY BIOPHARMA INC - DEAL FOR $48 PER SHARE IN CASH.ARRAY BIOPHARMA INC - DEAL FOR TOTAL ENTERPRISE VALUE OF APPROXIMATELY $11.4 BILLION.ARRAY BIOPHARMA INC - TRANSACTION VALUED AT $48 PER ARRAY SHARE IN CASH, FOR A TOTAL ENTERPRISE VALUE OF APPROXIMATELY $11.4 BILLION.ARRAY BIOPHARMA INC - PFIZER EXPECTS TO FINANCE MAJORITY OF DEAL WITH DEBT AND BALANCE WITH EXISTING CASH.ARRAY BIOPHARMA INC - BOARDS OF DIRECTORS OF BOTH COMPANIES HAVE APPROVED MERGER.ARRAY BIOPHARMA INC - TRANSACTION IS EXPECTED TO BE DILUTIVE TO PFIZER'S ADJUSTED DILUTED EPS BY $0.04 -$0.05 IN 2019.ARRAY BIOPHARMA INC - UPON CLOSE OF TRANSACTION, ARRAY'S EMPLOYEES WILL JOIN PFIZER.ARRAY BIOPHARMA INC - DEAL EXPECTED TO BE DILUTIVE TO PFIZER'S ADJUSTED DILUTED EPS BY $0.04 -$0.05 IN 2020, NEUTRAL IN 2021.ARRAY BIOPHARMA INC - PFIZER EXPECTS TO COMPLETE ACQUISITION IN SECOND HALF OF 2019.ARRAY BIOPHARMA INC - TRANSACTION IS EXPECTED TO BE ACCRETIVE TO PFIZER BEGINNING IN 2022.ARRAY BIOPHARMA INC - PLANS TO MAINTAIN PRODUCTIVE RESEARCH UNIT IN BOULDER TO COMPLEMENT PFIZER'S RESEARCH HUBS.ARRAY BIOPHARMA - AGREEMENT CONTEMPLATES THAT PFIZER WILL ACQUIRE ANY SHARES OF ARRAY THAT ARE NOT TENDERED INTO OFFER THROUGH A SECOND-STEP MERGER.ARRAY BIOPHARMA INC - PFIZER WILL PROVIDE ANY UPDATES TO ITS CURRENT 2019 GUIDANCE IN CONJUNCTION WITH ITS Q3 2019 EARNINGS RELEASE.  Full Article

Array BioPharma Reports Q4 Loss Per Share $0.25
Tuesday, 14 Aug 2018 

Aug 14 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR OF FISCAL 2018.Q4 LOSS PER SHARE $0.25.Q4 EARNINGS PER SHARE VIEW $-0.24 -- THOMSON REUTERS I/B/E/S.Q4 REVENUE $35.4 MILLION VERSUS I/B/E/S VIEW $38.7 MILLION.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF JUNE 30, 2018 WERE $413 MILLION.  Full Article

Array Biopharma Receives FDA Breakthrough Therapy Designation For Braftovi™ In Combination With Mektovi® And Cetuximab
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR BRAFTOVI™ IN COMBINATION WITH MEKTOVI® AND CETUXIMAB FOR BRAFV600E-MUTANT METASTATIC COLORECTAL CANCER.ARRAY BIOPHARMA INC - FDA BREAKTHROUGH THERAPY DESIGNATION BASED ON PHASE 3 BEACON CRC SAFETY LEAD-IN DATA.  Full Article

Array Biopharma Says CHMP Recommendation For Braftovi + Mektovi Will Now Be Reviewed By European Commission
Friday, 27 Jul 2018 

July 27 (Reuters) - Array Biopharma Inc ::BRAFTOVI™ (ENCORAFENIB) + MEKTOVI® (BINIMETINIB) RECEIVES POSITIVE CHMP OPINION FOR ADVANCED BRAF-MUTANT MELANOMA.ARRAY BIOPHARMA - CHMP RECOMMENDATION FOR BRAFTOVI + MEKTOVI WILL NOW BE REVIEWED BY EUROPEAN COMMISSION; FINAL EC DECISION EXPECTED BY END OF SEPT..  Full Article

Array Biopharma Announces FDA Approval Of Braftovi In Combination With Mektovi
Wednesday, 27 Jun 2018 

June 27 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA ANNOUNCES FDA APPROVAL OF BRAFTOVI™ (ENCORAFENIB) IN COMBINATION WITH MEKTOVI® (BINIMETINIB).ARRAY BIOPHARMA INC - APPROVAL BASED ON PHASE 3 COLUMBUS TRIAL WHICH DEMONSTRATED NEARLY 15 MONTHS MEDIAN PROGRESSION-FREE SURVIVAL.  Full Article

Array Biopharma Reports Q3 Loss Per Share $0.11
Wednesday, 9 May 2018 

May 9 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER OF FISCAL 2018.Q3 LOSS PER SHARE $0.11.Q3 REVENUE $66.4 MILLION.Q3 REVENUE VIEW $31.7 MILLION -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2018 WERE $440 MILLION.  Full Article

Aslan Pharmaceuticals buys full global commercial rights for Varlitinib
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Aslan Pharmaceuticals Ltd <6497.TWO>::ASLAN PHARMACEUTICALS ACQUIRES FULL GLOBAL COMMERCIAL RIGHTS FOR VARLITINIB FROM ARRAY BIOPHARMA.ARRAY BIOPHARMA INC HAS GRANTED ASLAN FULL GLOBAL RIGHTS TO DEVELOP, MANUFACTURE AND COMMERCIALISE VARLITINIB​.ASLAN WILL MAKE AN UPFRONT PAYMENT OF $12 MILLION TO ARRAY ON SIGNATURE AND FURTHER PAYMENT OF UP TO $12 MILLION WITHIN NEXT 12 MONTHS​.ASLAN WILL MAKE UPFRONT PAYMENT TOGETHER WITH UP TO US$30 MILLION OF DEVELOPMENT AND US$75 MILLION OF COMMERCIAL MILESTONES.  Full Article

Array Biopharma Contributes Rights And Assets Related To Arry-797 Drug Program To Yarra Therapeutics
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA SAYS ON DEC 21, CO CONTRIBUTED CERTAIN RIGHTS AND ASSETS RELATED TO ARRY-797 DRUG PROGRAM TO YARRA THERAPEUTICS - SEC FILING.ARRAY BIOPHARMA SAYS FORMED YARRA TO FURTHER DEVELOP, COMMERCIALIZE THERAPEUTICS TARGETED TOWARDS RARE DISEASES, INCLUDING ARRY-797 DRUG PROGRAM.ARRAY BIOPHARMA - YARRA WILL BE LED BY BRYAN STUART, WHO WILL SERVE AS YARRA'S PRESIDENT AND CHIEF EXECUTIVE OFFICER.  Full Article

Array BioPharma Announces Strategic Collaboration With Pfizer
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA ANNOUNCES STRATEGIC COLLABORATION WITH PFIZER.ARRAY BIOPHARMA SAYS UNDER COLLABORATION AGREEMENT, TRIAL WILL BE SPONSORED AND FUNDED BY PFIZER, WITH ARRAY PROVIDING BINIMETINIB SUPPLY.ARRAY BIOPHARMA - PHASE 1B CLINICAL STUDY IS EXPECTED TO BEGIN BY Q3 2018.ARRAY BIOPHARMA - ENTERED INTO CLINICAL TRIAL AGREEMENT WITH PFIZER TO INVESTIGATE SAFETY, EFFICACY OF SEVERAL NOVEL ANTI-CANCER COMBINATIONS.  Full Article

Array - In Exchange For $126.06 Million 3.00% Convertible Senior Notes Co Issued 2024 $126.06 Million Notes
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA - ‍ON DEC 1, IN EXCHANGE FOR $126.06 MILLION OF 3.00% CONVERTIBLE SENIOR NOTES DUE 2020 CO ISSUED 2024 NOTES OF $126.06 MILLION.ARRAY BIOPHARMA SAYS ‍2024 NOTES WILL MATURE ON DEC 1, 2024​ - SEC FILING.ARRAY - ALSO ISSUED AGGREGATE OF ABOUT 7.96 MILLION SHARES OF CO'S COMMON STOCK IN EXCHANGE OF $126.06 MILLION OF 3.00% CONVERTIBLE SENIOR NOTES DUE 2020​.ARRAY BIOPHARMA - ‍2024 NOTES TO BEAR INTEREST AT 2.625% PAYABLE SEMIANNUALLY IN ARREARS ON JUNE 1 & DEC 1 OF EACH YEAR, BEGINNING JUNE 1, 2018​.  Full Article

PRESS DIGEST - Wall Street Journal - June 18

June 18 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.